Definitive Contract HHSN261201700015C
Award Date
9/19/17
Potential Completion Date
6/18/18
Potential Value
$298K
Federal Agency
National Cancer Institute
Awardee
Mimetas US Inc.
Ultimate Awardee
Not listed
NAICS Category
541711 - Research and Development in Biotechnology
PSC Category
Q301 - Reference Laboratory Testing
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Potomac, MD 20850, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
8
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $2,000,000 Small Business Innovation Research (SBIR) Phase II contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Mimetas US Inc., a self-certified small disadvantaged business based in Montgomery Village, Maryland. The contract is for the development of a 3D perfusable platform for high-throughput screening (HTS) across diverse racial/ethnic cancer specimens. This system aims to enable personalized medicine approaches...
The Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Center for Advancing Translational Sciences awarded a Small Business Innovation Research (SBIR) Phase II contract to Mimetas US, Inc., a self-certified small disadvantaged business, to develop and evaluate the HEPAPLATE IPS, a high-throughput organ-on-a-chip in vitro hepatotoxicity screening platform. The $1,500,000.00 firm fixed price contract was awarded on February 8, 2018, with a completion date of...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), to Mimetas US Inc., a self-certified small disadvantaged business. The $224,998 Firm Fixed Price contract is for the "Development and Evaluation of the HepaPlate IPS: A High Throughput Organ on a Chip IPS Hepatotoxicity Screening Platform." The contract aims to develop and evaluate a high-throughput organ-on-a-chip...
This is a Phase II Small Business Innovation Research (SBIR) contract awarded by the National Cancer Institute (NCI), a civilian agency of the U.S. Department of Health and Human Services (HHS), to Nortis Inc., a for-profit manufacturer of biotechnology products and services. The contract, valued at $1,988,728.00, is for the development of a "vascularized tumor-microenvironment assay" to support the screening of anti-cancer drugs. This contract is designated as a Total Small Business...
The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a Small Business Innovation Research (SBIR) Phase I contract to Phenomapper, LLC, a minority-owned, self-certified small disadvantaged business located in San Jose, California. The $398,952.00 firm-fixed-price contract was awarded on September 16, 2020, with a completion date of September 15, 2021. The contract is for the development of artificial intelligence-aided imaging technology...
The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a Small Business Innovation Research (SBIR) Phase I contract to Diagnologix, LLC, a self-certified small disadvantaged business, for the development of "SBIR 360: A SIMPLE END-TO-END SYSTEM FOR SERIAL CELL SORTING AND MANIPULATION USING A SINGLE CONTAINER." The firm-fixed-price contract, with a potential value of $350,000.00, has a completion date of August 31, 2018. This SBIR...
<p>This SBIR Phase I contract was awarded by the National Cancer Institute (NCI), a civilian federal agency, to Transgenex Nanobiotech Inc., a minority-owned small business, for the development of a "fibrous scaffold-induced spheroids mimicking TME" solution. The contract, valued at $299,992.00, is a definitive, firm fixed-price contract with a completion date of July 21, 2014. The contract was set aside for the participation of small businesses.</p>
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Detroit R&D, Inc., a minority-owned, economically disadvantaged, woman-owned small business. The contract is for R&D in biomedical basic research with a ceiling value of $299,097. The contract is a definitive, firm-fixed-price contract with a period of performance ending on September 21, 2016. This SBIR Phase I award will support the development of...
This is a $388,108 firm-fixed price contract awarded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), to Gradient Health, Inc., a minority-owned small business. The contract is for a research and development project titled "Advancing Equity and Diversity in Breast Cancer Screening: Creating a Foundational Dataset and Toolset." This award is part of the NIH and Centers for Disease Control and Prevention (CDC) Small Business Innovation Research...
<p>The U.S. Department of Health and Human Services' National Institutes of Health National Cancer Institute awarded a Small Business Innovation Research (SBIR) Phase I firm-fixed-price contract to Mediomics LLC, a woman-owned small business, to develop novel tools for site-specific quantitative analysis of RNA modifications. The contract has a potential value of $248,357.00 and a completion date of June 18, 2018.</p>